BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

842 related articles for article (PubMed ID: 15879128)

  • 21. Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.
    Song MK; Lee SW; Suh YS; Lee KJ; Sung YC
    J Virol; 2000 Mar; 74(6):2920-5. PubMed ID: 10684312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
    Diniz MO; Lasaro MO; Ertl HC; Ferreira LC
    Clin Vaccine Immunol; 2010 Oct; 17(10):1576-83. PubMed ID: 20739505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
    Eo SK; Gierynska M; Kamar AA; Rouse BT
    J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
    Piechocki MP; Pilon SA; Wei WZ
    J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.
    Tritel M; Stoddard AM; Flynn BJ; Darrah PA; Wu CY; Wille U; Shah JA; Huang Y; Xu L; Betts MR; Nabel GJ; Seder RA
    J Immunol; 2003 Sep; 171(5):2538-47. PubMed ID: 12928404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Priming protective CD8 T cell immunity by DNA vaccines encoding chimeric, stress protein-capturing tumor-associated antigen.
    Schirmbeck R; Riedl P; Kupferschmitt M; Wegenka U; Hauser H; Rice J; Kröger A; Reimann J
    J Immunol; 2006 Aug; 177(3):1534-42. PubMed ID: 16849460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
    Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
    Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.
    Lin T; Liang S; Meng F; Han Q; Guo C; Sun L; Chen Y; Liu Z; Yu Z; Xie H; Ding J; Fan D
    Clin Exp Immunol; 2006 May; 144(2):319-25. PubMed ID: 16634806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
    Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
    Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen.
    Schirmbeck R; Zheng X; Roggendorf M; Geissler M; Chisari FV; Reimann J; Lu M
    J Immunol; 2001 Jan; 166(2):1405-13. PubMed ID: 11145726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
    Allen TM; Vogel TU; Fuller DH; Mothé BR; Steffen S; Boyson JE; Shipley T; Fuller J; Hanke T; Sette A; Altman JD; Moss B; McMichael AJ; Watkins DI
    J Immunol; 2000 May; 164(9):4968-78. PubMed ID: 10779808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus.
    Sedegah M; Weiss W; Sacci JB; Charoenvit Y; Hedstrom R; Gowda K; Majam VF; Tine J; Kumar S; Hobart P; Hoffman SL
    J Immunol; 2000 Jun; 164(11):5905-12. PubMed ID: 10820272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor.
    Iwasaki A; Barber BH
    Cancer Immunol Immunother; 1998 Jan; 45(5):273-9. PubMed ID: 9439651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
    Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
    J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8
    Kanuma T; Yamamoto T; Kobiyama K; Moriishi E; Masuta Y; Kusakabe T; Ozasa K; Kuroda E; Jounai N; Ishii KJ
    J Immunol; 2017 Jun; 198(12):4707-4715. PubMed ID: 28507029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.